In the Computational Oncology Group we are tackling some of the deadliest cancers by targeting the causes of chromosomal instability. Pancreatic, oesophageal, lung and ovarian cancers have the lowest survival rates, but they also share a common trait which we can exploit − extreme chromosomal instability (CIN). By therapeutically targeting CIN, we aim to improve outcomes in these tumours.

Our main research areas include:

• Using tumour organoids to develop therapeutic strategies to target CIN.
• Predicting therapy response using genomic signatures of CIN in patient biopsies.
• Developing single cell/nucleus sequencing approaches to detect ongoing CIN.

We are applying these technologies at the earliest stages of tumour development in patients with premalignant lesions, with the goal of preventing aggressive, difficult to treat cancers.